| Date | Title | | | 11/23/11 | Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference| Live Audio Webcast Wednesday, November 30, 2011
SAN DIEGO, Nov. 23, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 23rd Annual Piper Jaffray Health Care Conference in New York.
The live presentation takes place on Wednesday, November 30, 2011 at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. The presentation will be webcast and may ... |
|  | | 11/03/11 | Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference| Live Audio Webcast Wednesday, November 9, 2011
SAN DIEGO, Nov. 3, 2011 /PRNewswire via COMTEX/ --SAN DIEGO, Nov. 3, 2011 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 2011 Credit Suisse Annual Health Care Conference in Phoenix.
The live presentation takes place on Wednesday, November 9, 2011 at 4:00 p.m. Eastern Time / 2:00 p.m. Mountain Time / 1:00 p.m. Pacific T... |
| | | 10/31/11 | Neurocrine Biosciences Reports Third Quarter 2011 Results| COMPANY RECEIVES $30 MILLION IN MILESTONES DURING THE QUARTER
SAN DIEGO, Oct. 31, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2011.
For the third quarter of 2011, the Company reported net income of $31.4 million, or $0.56 per fully diluted share outstanding, compared to net income of $3.3 million, or $0.06 per fully diluted share outstanding, for the same period in 2010. For the nine m... |
| | | 10/26/11 | Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results| Earnings Release, Conference Call and Webcast After Close of Market, October 31, 2011
SAN DIEGO, Oct. 26, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2011 financial results after the Nasdaq market closes on Monday, October 31, 2011. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Monday afternoon, October 31, 2011 at 5:00 p.... |
| | | 10/04/11 | Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement| SAN DIEGO, Oct. 4, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has achieved its second milestone in its collaboration with Abbott for elagolix and next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. The Company and Abbott held a pre- phase III meeting with the FDA, the outcome of which generated a $20 million milestone payment from Abbott to the Company. This milestone event brings the total milestones achieved by the... |
| | | 09/27/11 | Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine| DATA FROM DAISY PETAL STUDY WILL BE PRESENTED
SAN DIEGO, Sept. 27, 2011 /PRNewswire via COMTEX/ --
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that an elagolix podium presentation has been accepted for the scientific program at the 2011 Annual Meeting of the American Society for Reproductive Medicine, to be held October 15-19, 2011 in Orlando, Florida. This annual meeting draws over 4,000 experts from around the world to address current topics related to human reproduction.
... |
| | | 09/19/11 | Neurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment in Second Phase II Clinical Trial| INVESTIGATIONAL NEW DRUG APPLICATION ACCEPTED BY FDA
SAN DIEGO, Sept. 19, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a second Phase II clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this second Phase II study is a randomized, double-blind, placebo controlled, cross-over trial, using a within-subject comparison for safety and efficacy evaluation. This 32 patient study ... |
| | | 09/13/11 | Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference| Live Audio Webcast Tuesday, September 20, 2011
SAN DIEGO, Sept. 13, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the UBS Global Life Sciences Conference in New York.
The live presentation takes place on Tuesday, September 20, 2011 at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on ... |
| | | 09/13/11 | Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids| RECEIVES MILESTONE PAYMENT OF $10 MILLION UNDER ABBOTT COLLABORATION AGREEMENT
SAN DIEGO, Sept. 13, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids. The initiation of this trial triggered a $10 million milestone payment from Abbott to the Company.
"We are pleased ... |
| | | 09/01/11 | Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference| Live Audio Webcast Thursday, September 8, 2011
SAN DIEGO, Sept. 1, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Stifel Nicolaus 2011 Healthcare Conference in Boston.
The live presentation takes place on Thursday, September 8, 2011 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time. The presentation will be webcast and may be accesse... |
| | | 07/28/11 | Neurocrine Biosciences Reports Second Quarter 2011 Results| VMAT2 PROGRAM CONTINUES TO PROGRESS
SAN DIEGO, July 28, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2011. For the second quarter of 2011, the Company reported net income of $2.0 million, or $0.04 per share, compared to a net loss of $5.2 million, or $0.09 loss per share, for the same period in 2010. For the six months ended June 30, 2011, the Company reported net income of $4.9 million, or $0.09... |
| | | 07/21/11 | Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results|
EARNINGS RELEASE AFTER CLOSE OF MARKET, JULY 28, 2011
CONFERENCE CALL AND WEBCAST SCHEDULED FOR JULY 29, 2011
SAN DIEGO, July 21, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2011 financial results after the Nasdaq market closes on Thursday, July 28, 2011. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Friday morning, July 2... |
| | | 06/23/11 | Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor| VMAT2 PRE-INVESTIGATIONAL NEW DRUG APPLICATION MEETING WITH FDA COMPLETED
SAN DIEGO, June 23, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. The Notice of Allowance indicates that a composition of matter patent on NBI-98854 will have an initial patent term extending ... |
| | | 06/16/11 | Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis| DATA FROM DAISY PETAL STUDY WILL BE PRESENTED IN THREE SESSIONS
SAN DIEGO, June 16, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that three elagolix presentations have been accepted for the scientific program at 2011 World Congress on Endometriosis, to be held September 4-7, 2011 in Montpellier, France. This important meeting is sponsored by the World Endometriosis Society and occurs every three years, bringing together clinicians and basic scient... |
| | | 05/31/11 | Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference| LIVE AUDIO WEBCAST TUESDAY, JUNE 7, 2011
SAN DIEGO, May 31, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2011 Global Healthcare Conference in New York.
The live presentation takes place on Tuesday, June 7, 2011 at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the C... |
| | | 05/03/11 | Neurocrine Biosciences Reports First Quarter 2011 Results| COMPANY PROVIDES UPDATE ON ELAGOLIX END OF PHASE II MEETING
SAN DIEGO, May 3, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2011. For the first quarter of 2011, the Company reported net income of $2.9 million, or $0.05 per share, compared with a net loss of $8.6 million, or $0.19 per share, for the same period in 2010. This $11.5 million improvement in operating results is primarily due to the ... |
| | | 04/29/11 | Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2011 Financial Results|
Earnings release after close of market, May 3, 2011
Conference Call and Webcast Scheduled for Wednesday, May 4, 2011
SAN DIEGO, April 29, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2011 financial results after the Nasdaq market closes on Tuesday, May 3, 2011. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday morning,... |
| | | 04/27/11 | Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference| Live Audio Webcast Wednesday, May 4, 2011
SAN DIEGO, April 27, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Deutsche Bank 36th Annual Healthcare Conference in Boston.
The live presentation takes place on Wednesday, May 4, 2011 at 10:40 a.m. Eastern Time / 7:40 a.m. Pacific Time. The presentation will be webcast and may be accessed on ... |
| | | 04/05/11 | Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor| SAN DIEGO, April 5, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. Based on this data, the Company is initiating the Investigational New Drug (IND) application process with the U.S. Food and Drug Administration (FDA).
"We are very pleased with these pr... |
| | | 03/30/11 | Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference| Live Audio Webcast Wednesday, April 6, 2011
SAN DIEGO, March 30, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 10th Annual Needham Healthcare Conference in New York City.
The live presentation takes place on Wednesday, April 6, 2011 at 1:20 p.m. Eastern Time / 10:20 a.m. Pacific Time. The presentation will be webcast and may be accesse... |
| | | 03/08/11 | Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference| Live Audio Webcast Tuesday, March 15, 2011
SAN DIEGO, March 8, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 23rd Annual OC Growth Stock Conference in Laguna Niguel, CA.
The live presentation takes place on Tuesday, March 15, 2011 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. The presentation will be webcast and may be access... |
| | | 03/02/11 | Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference| LIVE AUDIO WEBCAST WEDNESDAY, MARCH 9, 2011
SAN DIEGO, March 2, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen & Co. 31st Annual Health Care Conference in Boston.
The live presentation takes place on Wednesday, March 9, 2011 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time. The presentation will be webcast and may be access... |
| | | 02/23/11 | Neurocrine Biosciences to Present at Citi's 2011 Global Health Care Conference| Live Audio Webcast Tuesday, March 1, 2011
SAN DIEGO, Feb. 23, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at Citi's 2011 Global Health Care Conference in New York.
The live presentation takes place on Tuesday, March 1, 2011 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Compa... |
| | | 02/10/11 | Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results| SAN DIEGO, Feb. 10, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter and year ended December 31, 2010.
For the fourth quarter of 2010, the Company reported net income of $2.5 million, or $0.05 per basic share, compared with a net loss of $7.9 million, or $0.20 per basic share, for the same period in 2009. For the year ended December 31, 2010, the Company reported a net loss of $8.0 million, or $0.15 per basic sh... |
| | | 02/03/11 | Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results| CONFERENCE CALL AND WEBCAST SCHEDULED FOR THURSDAY, FEBRUARY 10, 2011
SAN DIEGO, Feb. 3, 2011 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2010 financial results after the Nasdaq market closes on Thursday, February 10, 2011. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, February 10, 2011 at 5:00 p... |
| |
|
